Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells.

ABSTRACT:

Background

Airway inflammation is a key feature of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroids (ICS) remain the main treatment for airway inflammation. Studies have noted the increased efficacy of ICS and long-acting beta 2 agonist (LABA) combination therapy in controlling exacerbations and improving airway inflammation than either monotherapy. Further studies have suggested that LABAs may have inherent anti-inflammatory potential, but this has not been well-studied.

Objective

We hypothesize that the LABA olodaterol can inhibit airway inflammation resulting from exposure to respiratory syncytial virus (RSV) via its binding receptor, the β2-adrenergic receptor.

Methods

Human bronchial epithelial brushing from patients with and without COPD

SUBMITTER: Yang N 

PROVIDER: S-EPMC7901009 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature